Eduardo Ramacciotti

TL;DR: In this paper, the authors compared the efficacy and safety of therapeutic versus prophylactic anticoagulation in patients hospitalised with COVID-19 in 31 sites in Brazil, and found that in the case of stable patients, in-hospital oral rivaroxaban (20 mg or 15 mg daily) or initial subcutaneous enoxaparin (1 mg/kg twice per day) or intravenous unfractionated heparin (to achieve a 0·3-0·7 IU/mL anti-Xa concentration) for clinically unstable patients, followed

TL;DR: In this article , patients hospitalised with COVID-19 at increased risk for venous thromboembolism were randomly assigned (1:1) to receive, at hospital discharge, rivaroxaban 10 mg/day or no anticoagulation for 35 days.

TL;DR: There are some situations in which assessment of anticoagulant effect may aid treatment decisions and the specialized coagulation assays that have been developed to measure the anticoaggulant effects of the new oral antICOagulants are identified.

TL;DR: The VeinViewer prototype could identify veins that were invisible to the naked eye and too shallow for ultrasound detection and may help in finding feeder veins during phlebectomy and in guiding laser and sclerotherapy treatments.

TL;DR: Microparticles appear to be an important element in venous thrombogenesis and the associated tissue factor activity in wild-type, in gene-deleted for E- and P- selectins and with high levels of P-selectin expression after the initiation of venousThrombosis in mice.